An open label multicentric phase 1 study of selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms.
Phase of Trial: Phase I
Latest Information Update: 26 Jan 2013
At a glance
- Drugs P 276 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Piramal Enterprises
- 31 Dec 2008 Planned number of patients changed from 40 to 28.
- 31 Dec 2008 Planned end date changed from 1 Aug 2008 to 1 Oct 2008.
- 16 Jul 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.